Article Type
Review
Published
This review synthesizes the pathophysiology and key aspects of bronchiectasis–COPD overlap syndrome and analyses the clinical evidence for brensocatib as the first potential disease-modifying therapy for this neutrophilic endotype designed to break the cycle.